# Besifloxacin-Eluting Contact Lens Review: Sustained Delivery
> A comprehensive review of besifloxacin-eluting contact lenses for treating bacterial keratitis, featuring 21.6x higher drug bioavailability than eye drops.

Tags: bacterial-keratitis, ophthalmology, drug-delivery-systems, contact-lenses, pharmacokinetics, besifloxacin, biomedical-engineering
## Introduction: Bacterial Keratitis
* Bacterial keratitis is a leading cause of corneal blindness globally.
* Current standard care involves hourly antibiotic eye drops, which have <7% ocular bioavailability.

## Besifloxacin-Eluting Contact Lens (BXF-CL)
* First-ever besifloxacin-eluting lens system utilizing an EC/RSPO polymer reservoir.
* Designed for sustained 24-hour drug release to replace intensive topicals.

## Fabrication and Characterization
* Drug-polymer film embedded in the lens periphery to maintain a 5.2 mm clear central optical zone.
* Physical properties (light transmittance and water content) are comparable to commercial contact lenses.

## Stability and Sterilization
* Drug integrity is preserved for 2 years when stored in a dry state at 4°C.
* Gamma irradiation confirmed as the optimal terminal sterilization method (Autoclaving causes drug leaching).

## Pharmacokinetic Results
* **Cmax:** 21.6x higher peak drug concentration in aqueous humor compared to hourly eye drops.
* **AUC:** 18.3x higher total drug exposure.
* Bioavailability is significantly improved by maintaining a constant concentration gradient and protecting the drug film between the lens and cornea.

## Safety and Efficacy
* Proven antimicrobial efficacy against S. aureus and E. coli.
* Cytocompatible with human corneal epithelial cells per ISO 10993.
* Non-irritative findings in Draize ocular irritation tests on rabbit models.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.